The EXCEL Registry of Patients Requiring ECMO

Sponsor
Australian and New Zealand Intensive Care Research Centre (Other)
Overall Status
Recruiting
CT.gov ID
NCT03793257
Collaborator
National Health and Medical Research Council, Australia (Other), Extracorporeal Life Support Organization (Other), National Heart Foundation, Australia (Other), The Alfred (Other), Barwon Health (Other), Fiona Stanley Hospital (Other), The Prince Charles Hospital (Other), Royal Prince Alfred Hospital, Sydney, Australia (Other), St Vincent's Hospital, Sydney (Other)
2,000
31
70.6
64.5
0.9

Study Details

Study Description

Brief Summary

ECMO is associated with significant costs, risks and requires specialist training and expertise. EXCEL is a novel, high-quality, detailed prospective registry of patients requiring ECMO in Australia and New Zealand. The registry provides information on patient selection, complications, costs and patient reported outcome measures. EXCEL uses the Theoretical Domains Framework to identify evidence-practice gaps and explore barriers and enablers to tailor implementation of evidence

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The aim of EXCEL is to generate a bi-national multidisciplinary network of integrated care for patients suffering acute cardiac or respiratory failure or cardiac arrest requiring extracorporeal membrane oxygenation (ECMO) to monitor long term outcomes and identify best practice.

    Each year around 130,000 Australians and New Zealanders are admitted to an intensive care unit (ICU). The sickest patients in the ICU who have severe failure of the heart or lungs may require an external machine to oxygenate their blood in addition to a mechanical ventilator. This intervention, called extracorporeal membrane oxygenation (ECMO), involves circulating all of the patient's blood through large cannulae to external machinery every minute. It has the capability of completely replacing a non-functioning heart or lungs for days to weeks on end. These critically ill patients who require ECMO are the sickest in the hospital with only 42% hospital survival. The use of ECMO has doubled in Australia and New Zealand and globally over five years, and in the USA has increased by 433%.

    The use of ECMO is associated with significant costs and risks, and it requires specialist training and expertise. In order to prepare for the organisation of these complex interventions in the ICU across regions, the investigators need to have accurate data on patients undergoing ECMO. The investigators monitor and review current practice in ECMO services by providing robust binational registry data to service providers and clinicians with a closed-loop feedback system. EXCEL explores barriers and enablers to evidence-based care in ECMO services and providing a platform to embed clinical trials. The investigators will translate findings with greater capacity, reach, and impact to drive measureable change in practice and improve patient-centred outcomes.

    The EXCEL Partnership represents a novel, coordinated effort to create a high-quality, detailed, prospective registry of patients requiring ECMO at ECMO centres. A tailored, detailed ECMO registry (EXCEL) can be used to address specific safety concerns, clinical questions and process of care issues. As a result, EXCEL can be designed and implemented to answer new investigator-initiated, hypothesis-driven clinical questions.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    2000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The EXCEL Registry: A Comprehensive Binational Registry on the Treatment and Outcomes of Patients Requiring ECMO
    Actual Study Start Date :
    Feb 1, 2019
    Anticipated Primary Completion Date :
    Dec 22, 2023
    Anticipated Study Completion Date :
    Dec 20, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Disability-free survival at 6 months, defined as alive and free of disability, measured with the World Health Organisation's Disability Assessment Schedule (WHODAS 2.0) score of <25%. [At 6 months from study enrolment]

      WHODAS 2.0 measured using a trained, blinded assessor via telephone interview. The WHODAS scores are calculated using the sum of the six domain scores. These domain scores are then converted to a metric score ranging from 0 to 100 (where 0= no disability; 100= full disability)

    Secondary Outcome Measures

    1. Number of participants with adverse events including major bleeding up to 28 days after ECMO, infection, thrombosis (in the ECMO cannulae or in the patient) and limb ischaemia [Up to 28 days after ECMO initiation]

      All adverse events are recorded determined by treating clinician

    2. Healthcare utilization -caseload per centre [Up to 12 months from study enrolment]

      ECMO patient numbers (caseload per centre)

    3. Healthcare utilization - ECMO initiation timing [Up to 12 months from study enrolment]

      Timing of ECMO initiation by staff including an ECMO retrieval team

    4. Healthcare utilization - Number of staff members required to manage ECMO [Up to 12 months from study enrolment]

      Staff numbers required for the provision of ECMO in ICU and the training required for these staff members to perform their role.

    5. Healthcare utilization - hospital length of stay [Up to 12 months from study enrolment]

      Hospital and in-patient rehabilitation length of stay including hospital readmissions and time spent in ICU

    6. Healthcare costs [Measured from ECMO commencement to hospital discharge until 6 months following hopsital admission.]

      Number of resources including staff and, equipment and blood products utilised whilst the patient was receiving hospital care until 6 months following hospital admission.

    7. Health-related quality of life at baseline, 6 and 12 months using the EQ5D-5L [At 6 and 12 months from study enrolment. Retrospective baseline measured at 6 months.]

      Measured using the EQ5D-5L, delivered by a trained, blinded assessor via telephone interview. The EQ5D includes an analogue scale that asks the patient to rate their health on a scale of 0 to 100. (Where 0= worst health imaginable; 100= best health imaginable)

    8. Number of patients with disability at 6 and 12 months [At 6 and 12 months from study enrolment]

      Measured using the WHODAS 2.0, delivered by a trained, blinded assessor via telephone interview

    9. Psychological function at 12 months [At 12 months from study enrolment]

      Measured using the EQ5D-5L, delivered by a trained, blinded assessor via telephone interview

    10. Return to work at 6 months [At 6 months from study enrolment]

      Return to work measured bu the WHODAS 2.0, delivered by a trained, blinded assessor via telephone interview

    11. Disability at baseline, 6 and 12 months [Measured at 6 and 12 months. Retrospective baseline disability measured at 6 months.]

      Patient reported disability using a disability scale, delivered by a trained, blinded assessor via telephone interview

    12. Activities of daily living at 6 and 12 months [Measured at 6 and 12 months]

      Activities of daily living measured at 6 and 12 month using the ADL and IADL, delivered by a trained, blinded assessor via telephone interview

    13. Cognitive function at 12 months [Measured at 12 months]

      Cognitive function measured at 12 months using the MOCA Blind, delivered by a trained, blinded assessor via telephone interview

    14. Number patients who survive to 12 months following ECMO initiation [At 12 months from study enrolment]

      Measured by Research Coordinators at each of the participating sites

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients admitted to ICU and receive ECMO in Australia and New Zealand

    • Patients aged 18 years or older

    Nil Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Canberra Hospital Canberra Australian Capital Territory Australia 2605
    2 Royal Prince Alfred Hospital Camperdown New South Wales Australia 2050
    3 St Vincent's Hospital Sydney Darlinghurst New South Wales Australia 2010
    4 Liverpool Hospital Liverpool New South Wales Australia 2170
    5 John Hunter Hospital Newcastle New South Wales Australia 2305
    6 Royal North Shore Hospital St Leonards New South Wales Australia 2065
    7 Prince of Wales Hospital Sydney New South Wales Australia 2031
    8 St George Hospital Sydney New South Wales Australia 2217
    9 Westmead Hospital Westmead New South Wales Australia 2145
    10 Royal Brisbane and Women's Hospital Brisbane Queensland Australia 4029
    11 Princess Alexandra Hospital Brisbane Queensland Australia 4102
    12 Prince Charles Hospital Chermside Queensland Australia 4032
    13 Gold Coast University Hospital Southport Queensland Australia
    14 Sunshine Coast University Hospital Sunshine Coast Queensland Australia 4575
    15 Townsville Hospital Townsville Queensland Australia 4814
    16 Royal Adelaide Hosptial Adelaide South Australia Australia 5000
    17 Flinders Medical Centre Adelaide South Australia Australia 5042
    18 Royal Hobart Hospital Hobart Tasmania Australia 7000
    19 Launceston General Hospital Launceston Tasmania Australia 7250
    20 Box Hill Hospital Box Hill Victoria Australia 3128
    21 Monash Medical Centre Clayton Victoria Australia 3168
    22 Frankston Hospital Frankston Victoria Australia 3199
    23 University Hospital Geelong Geelong Victoria Australia
    24 Austin Health Heidelberg Victoria Australia 3084
    25 The Alfred Hospital Melbourne Victoria Australia 3004
    26 St Vincent's Hospital Melbourne Melbourne Victoria Australia 3065
    27 Royal Melbourne Hospital Parkville Victoria Australia 3050
    28 Epworth Hospital Richmond Victoria Australia
    29 Sir Charles Gairdner Hospital Nedlands Western Australia Australia 6009
    30 Fiona Stanley Hospital Perth Western Australia Australia 6150
    31 Auckland City hospital Auckland New Zealand 1023

    Sponsors and Collaborators

    • Australian and New Zealand Intensive Care Research Centre
    • National Health and Medical Research Council, Australia
    • Extracorporeal Life Support Organization
    • National Heart Foundation, Australia
    • The Alfred
    • Barwon Health
    • Fiona Stanley Hospital
    • The Prince Charles Hospital
    • Royal Prince Alfred Hospital, Sydney, Australia
    • St Vincent's Hospital, Sydney

    Investigators

    • Study Chair: Carol L Hodgson, PhD, Australian and New Zealand Intensive Care Research Centre

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Australian and New Zealand Intensive Care Research Centre
    ClinicalTrials.gov Identifier:
    NCT03793257
    Other Study ID Numbers:
    • ANZIC-RC/CH003
    First Posted:
    Jan 4, 2019
    Last Update Posted:
    Mar 10, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Australian and New Zealand Intensive Care Research Centre
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 10, 2022